Skip to main content
Akeso, Inc. logo

Akeso, Inc. — Investor Relations & Filings

Ticker · 9926 ISIN · KYG0146B1032 LEI · 254900ECWYGR3QW5GF30 HKEX Manufacturing
Open in API
Filings indexed 335 across all filing types
Latest filing 2020-04-14 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 9926

About Akeso, Inc.

http://www.akesobio.com

Akeso, Inc. is a commercial-stage biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative antibody drugs globally. The company integrates comprehensive drug discovery capabilities, including target validation and antibody drug development. Akeso maintains a broad and innovative therapeutic portfolio, primarily concentrated in the fields of oncology and immunology. The company has successfully advanced multiple novel therapies, including five innovative drugs with approved indications, demonstrating its commitment to bringing breakthrough treatments to market. Akeso has notably developed a lung cancer drug that has garnered significant attention within the global biotech sector.

Recent filings

Filing Released Lang Actions
GLOBAL OFFERING
Regulatory Filings
2020-04-14 English
PHIP (1st submission)
Audit Report / Information Classification · 1% confidence The document is a 'PHIP' (Post-Hearing Information Proof) for Akeso, Inc., which is a standard preliminary document filed in the context of an Initial Public Offering (IPO) on the Hong Kong Stock Exchange (HKEX). The document structure lists various sections typical of a prospectus, such as 'Industry Overview', 'Business', 'Financial Information', and 'Accountants' Report'. Since the document is an announcement/index page providing links to the various sections of the IPO prospectus, it functions as a regulatory filing announcing the availability of the prospectus materials. FY 2019
2020-04-06 English
PHIP (1st submission)
Regulatory Filings
2020-04-06 English
Application Proof (1st submission)
Audit Report / Information Classification · 1% confidence The document is an 'Application Proof' for Akeso, Inc., which is a standard term used in the Hong Kong Stock Exchange (HKEX) for a preliminary prospectus filed during an Initial Public Offering (IPO) process. The content lists various sections typical of a prospectus, such as 'Risk Factors', 'Industry Overview', 'Business', 'Financial Information', and 'Accountants' Report'. Since the document is a preliminary offering document for a new listing, it falls under the category of 'POS' (which covers share issuance/capital changes) or more broadly, regulatory filings related to capital raising. Given the specific options, 'POS' is the most appropriate classification for a document detailing the structure of a share offering. FY 2019
2020-02-03 English
Application Proof (1st submission)
Regulatory Filings
2020-02-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.